.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Set up watchlists for daily email updates

► See Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

UBS
US Department of Justice
Colorcon
Dow
Moodys
Healthtrust
Johnson and Johnson
US Army
Argus Health
Boehringer Ingelheim

Generated: June 23, 2017

DrugPatentWatch Database Preview

Details for Patent: 7,897,646

« Back to Dashboard

Which drugs does patent 7,897,646 protect, and when does it expire?


Patent 7,897,646 protects SYMBICORT and is included in one NDA.

Protection for SYMBICORT has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has forty-four patent family members in thirty-five countries.

Summary for Patent: 7,897,646

Title:Use for budesonide and formoterol
Abstract:The invention provides the use of formoterol and budesonide in the treatment of chronic obstructive pulmonary disease.
Inventor(s): Bauer; Carl-Axel (Lund, SE), Trofast; Jan (Lund, SE)
Assignee: AstraZeneca AB (Sodertalje, SE)
Application Number:10/010,283
Patent Claim Types:
see list of patent claims
Use; Composition; Delivery;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Astrazeneca
SYMBICORT
budesonide; formoterol fumarate dihydrate
AEROSOL, METERED;INHALATION021929-002Jul 21, 2006RXYesYes7,897,646*PED► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 7,897,646

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Sweden9703407-8Sep 19, 1997

Non-Orange Book Patents for Patent: 7,897,646

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
2,006,189,587► Subscribe
8,461,211Use for budesonide and formoterol► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 7,897,646

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia757235► Subscribe
Brazil9812325► Subscribe
Canada2302700► Subscribe
China1271287► Subscribe
China1149998► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

UBS
Healthtrust
Farmers Insurance
Express Scripts
Mallinckrodt
Daiichi Sankyo
Fish and Richardson
Boehringer Ingelheim
Colorcon
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot